
Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew Lunning
Oncology Today with Dr Neil Love
00:00
I Think the E-Cog Trial Is Starting to Look a Little Bit Like Ebrutinib and Retuximab in a 65 Year Old Patient Population
There are 0 t53 mutated mantle cell and foma patients in if you never check for it right there's 10 percent 10 to 15 percent if you look for it and i'm not sure you should be doing this data set or br. If they get covid during maintenance retuximab that could be a problem so uh a lot more questions and answers coming out of triangle but i'm coming around to the data with more time, he says.
Transcript
Play full episode